1 / 11

Inspiration Biopharmaceuticals Study of Modified Recombinant Factor VIII OBI-1 in Subjects With Acquired Hemophilia A

OBI-1-301 Protocol Title . Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies. What is Acquired Hemophilia?. Ultra-orphan disease (1.5 cases/million/year)Presents in older popu

nyoko
Download Presentation

Inspiration Biopharmaceuticals Study of Modified Recombinant Factor VIII OBI-1 in Subjects With Acquired Hemophilia A

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Inspiration Biopharmaceuticals Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A Lunch & Learn Presentation

    2. OBI-1-301 Protocol Title Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies

    3. What is Acquired Hemophilia?

More Related